Risk Evaluation and Mitigation Strategy Experts Continue Interpreting New FDA REMS Guidance

Wilmington, DE, October 09, 2009 --(PR.com)-- Advisory to Medical Editors & Writers:

Recently, the FDA issued a very important draft guidance for pharmaceutical and biotechnology companies for formatting, assessing and modifying Risk Evaluation & Mitigation Strategies (REMS) to ensure the safe use of pharmaceutical products.

Jeffrey Fetterman and Dr. Gary Slatko, both principals of ParagonRx, have helped many companies prepare REMS and related safety plans. They have previously co-authored two books on the topic and are now reviewing and interpreting this draft FDA guidance in the third of a series of blog articles published at http://blog.paragonrx.com/.

Both experts are available for interviews and speaking engagements on this topic. They can be accessed by calling Kevin Fetterman at 302-504-0400, extension 236.

The new draft REMS guidance document and other REMS resources are also available at www.paragonrx.com.

###